

Andreas Reichel, Head of Research PK, Bayer

Andreas is Head of Research Pharmacokinetics (PK) for about ten years with responsibility for the departments in Berlin and Wuppertal which provide PK support to all drug discovery projects at Bayer Pharma in several therapeutic areas. His responsibility spans from lead generation and optimisation right through to candidate selection and profiling applying *in vitro* ADME assays, *in vivo* PK studies as well as PK and PK/PD modelling to predict the PK and the therapeutic dose in human. In 1994, Andreas received his PhD in Cell Biology from the University of Leipzig studying physiological transport processes at the blood-brain barrier (BBB) *in vivo* under the supervision of Prof. Armin Ermisch. From 1994 to 1997 he was working in the laboratories of Dr. David Begley and Prof. Joan Abbott, King's College London, where he became interested in *in vitro* models of the BBB. Funded by several pharmaceutical companies he also developed approaches to predict the CNS penetration of drugs. In 1997, Andreas joined Discovery DMPK at Hoffmann-La Roche, Basel, where he expanded his expertise to intestinal and hepatic transport processes and their relevance to drug absorption, drug disposition and drug-induced liver toxicity.